Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives

Abstract

The present invention relates to Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 7 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use in treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephritic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and methods of preparation thereof.

1 . A compound of formula (Ia) 
       
         
           
           
               
               
           
         
         R 1  is H,
 C 1-6 -alkyl optionally substituted by CN, 
 or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B, 
 or is —(CH 2 ) m —R a  wherein R a  is:
 CN, 
 OR i , 
 NR i R ii , or 
 C 3-6 -cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B, 
 
 or —(CH 2 ) n —(CO)—R b  or —(CH 2 ) n —(SO 2 )—R b , wherein R b  is:
 C 1-6 -alkyl, 
 C 1-6 -alkoxy, 
 C 3-6 -cycloalkyl, 
 —(CH 2 ) m —NR iii R iv , 
 NR i R ii , or 
 C 3-6 -cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B, 
 
 
         or R 1  and R 3  together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O; 
         there is one or more R 2 , wherein each R 2  is the same or different, 
         R 2  is one or more H, OH, halo, CN, nitro, C 1-6 -alkyl optionally substituted by —NR iii R iv , C 1-6 -alkoxy, —O—CH 2 —C 2-6 -alkenyl, or benzyloxy,
 or two R 2  together with the indole ring to which they are attached form an oxo or dioxo bridge; 
 
         R 3  is H,
 halo, 
 —(CO)—R c , wherein R c  is:
 C 1-6 -alkyl, 
 —(CH 2 ) n —NR i R ii , 
 —(CH 2 ) n —NR iii R iv , or 
 5 or 6 membered heterocycloalkyl optionally substituted by C 1-6 -alkyl, 
 or C 1-6 -alkyl or aryl, each of which is optionally substituted by halo, 
 —O(CO)—C 1-6 -alkyl, or 
 —NH(CO)R d , wherein R d  is C 1-6 -alkyl optionally substituted by halo or nitro, or R d  is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C 1-6 -alkyl or C 1-6 -haloalkyl; 
 
 
         there is one or more R 4 , wherein each R 4  is the same or different, 
         R 4  is one or more H, halo, C 1-6 -alkyl or C 1-6 -alkoxy
 or two R 4  together with the phenyl ring to which they are attached form an oxo or dioxo bridge; 
 
         R 7  is H,
 Cl, or 
 NR e R f , wherein R e  and R f  are each independently H or C 1-6 -alkyl or R e  and R f  together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by C 1-6 -alkyl, 
 
         or R 6  and R 7  together form a C═O group when the dotted line does not represent a double bond; 
         B is halo, CN, NR i R ii , C 1-6 -alkyl optionally substituted by CN, halo or C 1-6 -alkoxy, C 1-6 -alkoxy, C 1-6 -haloalkoxy, C 3-6 -cycloalkyl, —C(O)O—C 1-6 -alkyl, —C(O)NR i R ii , —C(O)—C 1-6 -alkyl, —S(O) 2 —C 1-6 -alkyl, —S(O) 2 —NR i R ii , (CR iii R iv ) n -phenyl, or (CR iii R iv ) n -5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
 halo, CN, NR i R ii , C 1-6 -alkyl optionally substituted by CN or C 1-6 -alkoxy, C 1-6 -alkoxy, C 1-6 -haloalkoxy, C 3-6 -cycloalkyl, —C(O)O—C 1-6 -alkyl, —C(O)—NR i R ii , —C(O)—C 1-6 -alkyl, —S(O) 2 —C 1-6 -alkyl, and —S(O) 2 —NR i R ii ; 
 
         R i  and R ii  are each independently H, C 1-6 -alkyl, C 1-6 -alkyl-NR iii R iv , —(CO)O—C 1-6 -alkyl, —C(O)—NR iii R iv , —S(O) 2 —C 1-6 -alkyl or —S(O) 2 —NR iii R iv ; 
         R iii  and R iv  are each independently H or C 1-6 -alkyl; 
         m is 1 to 6; and 
         n is 0 to 4; 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The compound of  claim 1 , wherein:
 R 1  is H,
 C 1-6 -alkyl optionally substituted by CN or C 1-6 -alkoxy, 
 aryl, 
 5 or 6 membered heteroaryl, 
 sulfonylaryl, 
 —(CH 2 ) m —R a  wherein R a  is C 3-6 -cycloalkyl, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more substituents selected from the group consisting of:
 halo, CN, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -haloalkoxy, —C(O)O—C 1-6 -alkyl and phenyl optionally substituted by halo, C 1-6 -alkyl, C 1-6 -haloalkyl or C 1-6 -alkoxy, 
 
 —(CH 2 ) m —NR i R ii  or, 
 —(CH 2 ) n —(CO)—R b , wherein R b  is aryl or 5 or 6 membered-heterocycloalkyl; 
   there is one or more R 2 , wherein each R 2  is the same or different,   R 2  is one or more H, halo, CN, nitro, C 1-6 -alkyl, C 1-6 -alkoxy, —O—CH 2 —C 2-6 -alkenyl, or benzyloxy,
 or two R 2  together with the indole ring to which they are attached form an oxo or dioxo bridge; 
   R 3  is H,
 halo, 
 —(CO)—R c , wherein R c  is C 1-6 -alkyl, 5 or 6 membered heterocycloalkyl optionally substituted by C 1-6 -alkyl, or R c  is —(CH 2 ) n —NR i R ii , or 
 C 1-6 -alkyl or aryl, each of which is optionally substituted by
 —O(CO)—C 1-6 -alkyl or 
 —NH(CO)R d , wherein R d  is C 1-6 -alkyl optionally substituted by halo or nitro, or R d  is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C 1-6 -alkyl or C 1-6 -haloalkyl; 
 
   there is one or more R 4 , wherein each R 4  is the same or different,   R 4  is one or more H, halo, C 1-6 -alkyl or C 1-6 -alkoxy
 or two R 4  together with the phenyl ring to which they are attached form an oxo or dioxo bridge; 
   R 7  is H,
 Cl, or 
 NR e R f , wherein R e  and R f  are each independently H or C 1-6 -alkyl or R e  and R f  together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocycloalkyl optionally substituted by C 1-6 -alkyl, 
   or R 6  and R 7  together form a C═O group when the dotted line does not represent a double bond;   R i  and R ii  are each independently selected from H, C 1-6 -alkyl and —(CO)O—C 1-6 -alkyl;   m is 1 to 6; and   n is 0 to 4;   or a pharmaceutically acceptable salt thereof.   
     
     
         3 . The compound of  claim 2 , wherein:
 R 1  is H,
 C 1-6 -alkyl optionally substituted by CN or by C 1-6 -alkoxy, 
 aryl, 
 5 or 6 membered heteroaryl, 
 sulfonylaryl, 
 —(CH 2 ) m —R a  wherein R a  is C 3-6 -cycloalkyl, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more substituents selected from the group consisting of:
 halo, CN, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -haloalkoxy, —C(O)O—C 1-6 -alkyl and phenyl optionally substituted by halo, C 1-6 -alkyl, C 1-6 -haloalkyl or C 1-6 -alkoxy, 
 
 —(CH 2 ) m —NR i R ii , or 
 —(CH 2 ) n —(CO)—R b , wherein R b  is aryl or 5 or 6 membered-heterocycloalkyl; 
   there is one or more R 2 , wherein each R 2  is the same or different,   R 2  is one or more H, halo, CN, nitro, C 1-6 -alkyl, C 1-6 -alkoxy, —O—CH 2 —C 2-6 -alkenyl, or benzyloxy,
 or two R 2  together with the indole ring to which they are attached form an oxo or dioxo bridge; 
   R 3  is H,
 halo, 
 —(CO)—R c , wherein R c  is C 1-6 -alkyl, 5 or 6 membered heterocycloalkyl optionally substituted by C 1-6 -alkyl, or R c  is —(CH 2 ) n —NR i R ii , or 
 C 1-6 -alkyl or aryl, each of which is optionally substituted by
 —O(CO)—C 1-6 -alkyl or 
 —NH(CO)R d , wherein R d  is C 1-6 -alkyl optionally substituted by halo or nitro, or R d  is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C 1-6 -alkyl or C 1-6 -haloalkyl; 
 
   there is one or more R 4 , wherein each R 4  is the same or different,   R 4  is one or more H, halo, C 1-6 -alkyl or C 1-6 -alkoxy
 or two R 4  together with the phenyl ring to which they are attached form an oxo or dioxo bridge; 
   R 7  is H,
 Cl, or 
 NR e R f , wherein R e  and R f  are each independently H or C 1-6 -alkyl or R e  and R f  together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by C 1-6 -alkyl, 
   R i  and R ii  are each independently selected from H, C 1-6 -alkyl and —(CO)O—C 1-6 -alkyl;   m is 1 to 6; and   n is 0 to 4;   or a pharmaceutically acceptable salt thereof.   
     
     
         4 . The compound of  claim 3 , wherein:
 R 1  is H,
 C 1-6 -alkyl optionally substituted by CN, or 
 —(CH 2 ) m —R a  wherein R a  is aryl, which is optionally substituted by one or more substituents selected from the group consisting of:
 halo, CN, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -haloalkoxy, —C(O)O—C 1-6 -alkyl and phenyl optionally substituted by halo, C 1-6 -alkyl, C 1-6 -haloalkyl or C 1-6 -alkoxy, 
 
   there is one or more R 2 , wherein each R 2  is the same or different,   R 2  is one or more H, halo or C 1-6 -alkoxy;   R 3  is H,
 —(CO)—R c , wherein R c  is C 1-6 -alkyl or 5 or 6 membered heterocycloalkyl optionally substituted by C 1-6 -alkyl, or 
 C 1-6 -alkyl; 
   R 4  is H;   R 7  is Cl or
 NR e R f , wherein R e  and R f  are each independently H or C 1-6 -alkyl or R e  and R f  together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by C 1-6 -alkyl, and 
   m is 1 to 6;   or a pharmaceutically acceptable salt thereof.   
     
     
         5 . The compound of  claim 4 , selected from the group consisting of:
 (1-Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-chloro-benzoimidazol-1-yl)-piperidin-1-yl]-methanone;   (1-Benzyl-2-methyl-1H-indol-3-yl)-{4-[2-(4-methyl-piperazin-1-yl)-benzoimidazol-1-yl]-piperidin-1-yl}-methanone;   (1-Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-morpholin-4-yl-benzoimidazol-1-yl)-piperidin-1-yl]-methan one;   (1-Benzyl-2-methyl-1H-indol-3-yl)-[4-(2-piperidin-1-yl-benzoimidazol-1-yl)-piperidin-1-yl]-methanone;   [4-(2-Chloro-benzoimidazol-1-yl)-piperidin-1-yl]-(2-methyl-1H-indol-3-yl)-methanone;   [4-(2-Dimethylamino-benzoimidazol-1-yl)-piperidin-1-yl]-(2-methyl-1H-indol-3-yl)-methanone; and   [4-(2-Methylamino-benzoimidazol-1-yl)-piperidin-1-yl]-(2-methyl-1H-indol-3-yl)-methanone.   
     
     
         6 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
         R 1  is H,
 C 1-6 -alkyl optionally substituted by CN, 
 or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B, 
 or is —(CH 2 ) m —R a  wherein R a  is:
 CN, 
 OR i , 
 NR i R ii , or 
 C 3-6 -cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B, 
 
 or —(CH 2 ) n —(CO)—R b  or —(CH 2 ) n —(SO 2 )—R b , wherein R b  is:
 C 1-6 -alkyl, 
 C 1-6 -alkoxy, 
 C 3-6 -cycloalkyl, 
 —(CH 2 ) m —NR iii R iv , 
 NR i R ii , or 
 C 3-6 -cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B, 
 
 
         or R 1  and R 3  together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O; 
         there is one or more R 2 , wherein each R 2  is the same or different, 
         R 2  is one or more H, OH, halo, CN, nitro, C 1-6 -alkyl optionally substituted by —NR iii R iv , C 1-6 -alkoxy, —O—CH 2 —C 2-6 -alkenyl, or benzyloxy,
 or two R 2  together with the indole ring to which they are attached form an oxo or dioxo bridge; 
 
         R 3  is H,
 halo, 
 —(CO)—R c , wherein R c  is:
 C 1-6 -alkyl, 
 —(CH 2 ) n —NR i R ii , 
 —(CH 2 ) n —NR iii R iv , or 
 5 or 6 membered heterocycloalkyl optionally substituted by C 1-6 -alkyl, 
 
 or C 1-6 -alkyl or aryl, each of which is optionally substituted by
 halo, 
 —O(CO)—C 1-6 -alkyl, or 
 —NH(CO)R d , wherein R d  is C 1-6 -alkyl optionally substituted by halo or nitro, or R d  is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C 1-6 -alkyl or C 1-6 -haloalkyl; 
 
 
         there is one or more R 4 , wherein each R 4  is the same or different, 
         R 4  is one or more H, halo, C 1-6 -alkyl or C 1-6 -alkoxy
 or two R 4  together with the phenyl ring to which they are attached form an oxo or dioxo bridge; 
 
         R 7  is H,
 Cl, or 
 NR e R f , wherein R e  and R f  are each independently H or C 1-6 -alkyl or R e  and R f  together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by C 1-6 -alkyl, 
 
         or R 6  and R 7  together form a C═O group when the dotted line does not represent a double bond; 
         B is halo, CN, NR i R ii , C 1-6 -alkyl optionally substituted by CN, halo or C 1-6 -alkoxy, C 1-6 -alkoxy, C 1-6 -haloalkoxy, C 3-6 -cycloalkyl, —C(O)O—C 1-6 -alkyl, —C(O)NR i R ii , —C(O)—C 1-6 -alkyl, —S(O) 2 —C 1-6 -alkyl, —S(O) 2 —NR i R ii , (CR ii R iv ) n -phenyl, or (CR iii R iv ) n -5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
 halo, CN, NR i R ii , C 1-6 -alkyl optionally substituted by CN or C 1-6 -alkoxy, C 1-6 -alkoxy, C 1-6 -haloalkoxy, C 3-6 -cycloalkyl, —C(O)O—C 1-6 -alkyl, —C(O)—NR i R ii , —C(O)—C 1-6 -alkyl, —S(O) 2 —C 1-6 -alkyl, and —S(O) 2 —NR i R ii ; 
 
         R i  and R ii  are each independently H, C 1-6 -alkyl, C 1-6 -alkyl-NR iii R iv , —(CO)O—C 1-6 -alkyl, —C(O)—NR iii R iv , —S(O) 2 —C 1-6 -alkyl or —S(O) 2 —NR iii R iv ; 
         R iii  and R iv  are each independently H or C 1-6 -alkyl; 
         m is 1 to 6; and 
         n is 0 to 4; 
         or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.